Dalrada Technology Group Ends Financing Agreements with IBS; Dispute Arises

What Happened Dalrada Technology Group, Inc. (through its wholly owned subsidiary Genefic, Inc.) announced it elected to terminate a set of financing agreements with IBS Equity Fund III, LLC and IBS Private Credit Fund IV, LLC. The original agreements (entered Dec 31, 2025) included a Master Performance Standby Letter of Credit and Guaranty Agreement (MGA) with a $20,000,000 standby facility and a Master Credit, Security, and Account Purchase Agreement (MCSPA) with a $5,000,000 credit/account purchase facility. Genefic notified IBS of its election to terminate on September 14, 2026; IBS sent notices dated September 15, 2026 (delivered Sept 16) asserting termination and triggering of rights under the agreements.

Key Details

• Financing agreements originally executed Dec 31, 2025; no funding was ever provided by IBS under those agreements (no loans, advances, purchases, or draws).
• Related documents included a Secured Promissory Note (original principal $181,500) and a Prefunded Warrant; the Company and Genefic received no cash from issuance.
• Dalrada is a party to the MCSPA as parent guarantor; CEO Brian Bonar executed a personal guaranty in favor of IBS Fund III.
• IBS asserts that termination does not release obligations or security interests until IBS’s asserted amounts are paid and other conditions to “Complete Termination” are met, and IBS has asserted early termination fees.

Why It Matters This filing signals a contractual dispute that could create contingent liabilities or lead to enforcement actions despite the company never having received financing proceeds. Although Dalrada states it intends to defend against IBS’s claims and believes it has meritorious defenses, investors should note the existence of personal and corporate guaranties and potential early termination fees that IBS may seek to collect. The company’s ability to raise future financing or potential exposure of pledged assets could be affected depending on the outcome of any claims or enforcement by IBS. The report also includes a standard caution that forward-looking statements are subject to risks and uncertainties.